KEYTRUDA
3 stories
-
healthNew mRNA Vaccine Combo Slashes Melanoma Recurrence Risk by 49%
Merck-Moderna personalized mRNA cancer vaccine plus KEYTRUDA reduces melanoma recurrence or death risk over five years.
-
healthGLP-1 Drugs Like Ozempic Show Broad Cancer Protection Promise
Multiple studies at ASCO 2024 show GLP-1 drugs reduce cancer risk and improve outcomes across tumor types, with potential benefits tied to inflammation reduction and weight loss.
-
healthmRNA Vaccine Slashes Melanoma Recurrence Risk in Landmark Trial
A new mRNA cancer therapy from Merck and Moderna cuts melanoma recurrence or death risk by 49% over five years, offering new hope for late-stage patients.